Clinical Trials Browser

Has results × Prostatic Neoplasms × siltuximab × Clear all

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Phase 2 Terminated

106 enrolled 13 charts

Neoplasms, Prostatic Neoplasms

NCT00433446 2013-02-05

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

62 enrolled 13 charts

Prostatic Neoplasms